Factors affecting glycemic control in patients with type 2 diabetes mellitus using oral antidiabetics: A single-center experience

In this retrospective study, we aimed to investigate the factors affecting glycemic control in patients with type 2 diabetes mellitus (DM) treated with oral antidiabetic drugs (OADs). From 2019 to 2020, type 2 DM patients treated with OADs were included in this study. Patients less than 18 years old and those treated with insulin were excluded from the study. The patients were divided into two groups according to HbA1C levels as follows: good glycemic control (GGC) (

PDF

___

1. Sullivan PW, Morrato EH, Ghushchyan V, et al. Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care. 2005;28:1599-603.

2. American Diabetes A. 2. Classification and diagnosis of diabetes. Diabetes Care. 2017;40(Suppl 1):11-24.

3. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-9.

4. Katon WJ, Rutter C, Simon G, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care. 2005;28:2668-72.

5. Tunceli K, Bradley CJ, Nerenz D, et al. The impact of diabetes on employment and work productivity. Diabetes Care. 2005;28:2662-7.

6. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-94.

7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53.

8. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.

9. Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197-206.

10. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93.

11. Pal K, Eastwood SV, Michie S, et al. Computer-based diabetes selfmanagement interventions for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013:CD008776.

12. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.

13. Onat A, Ozhan H, Esen AM, et al. Prospective epidemiologic evidence of a "protective" effect of smoking on metabolic syndrome and diabetes among doi: 10.5455/medscience.2020.09.179 Med Science 2021;10(1):46-50 50

Turkish women--without associated overall health benefit. Atherosclerosis. 2007;193:380-8.

14. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-44.

15. Gong Q, Zhang P, Wang J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the da qing diabetes prevention outcome study. Lancet Diabetes Endocrinol. 2019;7:452-61.

16. Association AD. 1. Improving care and promoting health in populations: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):7-13.

17. Clark CM, Jr., Kinney ED. Standards for the care of diabetes. Origins, uses and implications for third-party payment. Diabetes Care. 1992;15 Suppl 1:10-4.

18. Kirk A, Mutrie N, MacIntyre P, Fisher M. Increasing physical activity in people with type 2 diabetes. Diabetes Care. 2003;26:1186-92.

19. Amanat S, Ghahri S, Dianatinasab A, et al. Exercise and type 2 diabetes. Adv Exp Med Biol. 2020;1228:91-105.

20. Tekin Yanık Y, Erol Ö. Tip 2 diyabetli bireylerin öz-yeterlilik düzeylerinin değerlendirilmesi. J Anatolia Nursing Health Sci. 2016;19:166-74.

21. Rıza çitil YÖ, Osman Günay. Kayseri il merkezinde bir sağlık ocağında başvuran diyabetik hastalarda metabolik kontrol durumu ve eşlik eden faktörler. Erciyes Tıp Dergisi. 32:111-22.

22. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1- 452.

23. Navaneethan SD, Kirwan JP, Remer EM, et al. Adiposity, Physical Function, and Their Associations With Insulin Resistance, Inflammation, and Adipokines in CKD. Am J Kidney Dis. 2021;77:44-55.

24. Mahley RW, Palaoglu KE, Atak Z, et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res. 1995;36:839-59.

25. Bo S, Gentile L, Cavallo-Perin P, et al. Sex- and BMI-related differences in risk factors for coronary artery disease in patients with type 2 diabetes mellitus. Acta Diabetol. 1999;36:147-53.

26. Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975-80.

27. Khan HA, Sobki SH, Khan SA. Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia. Clin Exp Med. 2007;7:24-9.

28. Urrea C, Mignogna A. Development of an expert system for pre-diagnosis of hypertension, diabetes mellitus type 2 and metabolic syndrome. Health Informatics J. 2020:1460458220937095.

29. Mahato PG RV, Raut P Psd, Regmi P, et al Association between glycaemic control and serum lipid profile in type 2 diabetic patients: Glycated haemoglobin as a dual biomarker. Biomedical Research. 2011;22:375-80.